Estimation of average diagnosis and treatment costs of hepatitis C

Gastroenterology and Hepatology from Bed to Bench

Volumn 5, Issue 3, 2012, Pages 139-145

  Ashtari, Sara ^c   Vahedi, Mohsen ^b   Pourhoseingholi, Mohamad Amin ^a   Pourhoseingholi, Asma ^a   Safaee, Azadeh ^a   Moghimi Dehkordi, Bijan ^a   Zali, Mohammad Reza ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c NONE

Author keywords

Cost analysis; Hepatitis C; Interferon; Peg interferon

Indexed keywords

INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; CONSULTATION; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEPATITIS C; HOSPITALIZATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; TREATMENT DURATION;

EID: 84866496101     PISSN: 20082258     EISSN: 20084234     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13:2436-41. (Pubitemid 46929498)
2. Taylor MW, Tsukahara T, McClintick JN, Edenberg HJ, Kwo P. Cyclic changes in gene expression inducted by Peg- interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment. J Transl Med 2008; 5:66.
3. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iran Med 2005; 8:84-90. (Pubitemid 40613753)
4. Alavian SM. Hepatitis C virus infection: Epidemiology, risk factors and prevention strategies in public health in I.R.IRAN. Gastroenterol Hepatol Bed Bench 2010; 3:5-14.
5. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-67. (Pubitemid 41196755)
6. Alberti A, Benvegnu L. Management of hepatitis C. J Hepatol 2003; 38:s1 04-18.
7. Alavian SM. New globally faces of hepatitis B and C in the world. Gastroenterol Hepatol Bed Bench 2011; 4:171-74.
8. Merat SH, Rezvan H, Nouraie M, et al. Serprevalance of hepatitis C virus: the first population-based study from Iran. International Journal of Infectious Disease 2010;145:113-6.
9. Touzet S, Kraemer L, Colin C, Pradat P, Lainor D, Baily F, et al. Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the litreature. HENCORE Group. Hepatitis C European Network for Co-operative Resarch. Eur J Gastroenterol Hepatol 2000;12:667-78.
10. Wylez DL. Moving beyond interferon alfa: investigational drugs for hepatitis C virus infection. Top HIV Med 2010;18:132-36.
11. Alavian SM, Lankarani KB, Aalaei-Andabili SH, pouryasin A, Ebrahimi-Daryani N, Nassri-Toosi M, et al. Treatment of chronic hepatitis C infection: Update of the recommendation from scientific Lader's Meeting 28th July 2011-Tehran, IR Iran. Hepat Mon 2011; 11:703-13.
12. AhmadiPour MH, Alavian SM, Amini S, Azadmanesh k. Hepatitis C Virus Genotypes. Hepat Mon 2005;5:77-82.
13. Alavian SM, Tabatabaee SV, keshvari M, Behnava B, Miri SM, Elizee PK, et al. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-center study of 367 cases liver Int 2010;30:117-80.
14. McCombs J.S, Yuan Y, Shin J, Saab S. Economic Burden associated with patients diagnosed with hepatitis C. Clin Ther 2011; 33:1268-80.
15. Vahedi M, Pourhoseingholi A, Ashtari S, Pouhoseingholi MA, Karkhane M, Moghimi-Dehkordi B, et al. Using statistical models to assess medical cost of hepatitis C virus. Gastroenterol Hepatol Bed Bench 2012; 5(Suppl.1):S31-S6.
16. Dienstag JL, Isselbacher KJ. Harrison's principles of internal medicine. 16th edition. Mc Graw Hill publication 2005;285:1822-37.
17. Kenneth W, Lin M.D, Jeffrey T, Kirchner D.O. Lancaster General Hospital, Lancaster, Pennsylvania. Am Fam Physician 2004; 69:75-82.
18. kanwal F, Garlnek IM, Martin PM, Dulai GS, Farid M, Spiegel BM. treatment alternatives for hepatitis B cirrhosis: a cost-effective analysis. Ann intern Med 2005;142:821-83.
19. Rice DP. Cost of Illness Studies: What is good about them? Inj Pre 2000; 6:175-76.
20. Wong JB. Hepatitis C: cost of illness and consideration for the economic evaluation of antiviral therapies. Pharmacoeconomics 2006; 24:661-72. (Pubitemid 43998819)
21. Armstrong EP, Charland SL. Burden of illness of hepatitis C from a managed care organization perspective. Curr Med Res Opin 2004; 20:671-79. (Pubitemid 38685011)
22. Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, et al. Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database Syst Rev2002;(2):CD000370..
23. Poynard T, Mchutchison J, Goodman Z, Ling MH, Alberch J, et al. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000; 31:211-18. (Pubitemid 30033709)
24. Fried MW, Shiftman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
25. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. The Lancet 2003; 362:2095-100. (Pubitemid 38035201)
26. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, Management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
27. Roshandel D, Rezailashkajani M, Shafaee S, Zali MR. A cost analysis of functional bowel disorders in Iran. Int J Colorectal Dis 2007; 22:791-9. (Pubitemid 46863756)
28. Moghimi-Dehkordi B, Vahedi M, Mansoori B, Kasaeian A, Safaee A, Pourhoseingholi A, et al. Economic burden of gastro-oesophageal reflux disease and dyspepsia: A community-based study. Arab J Gastroenterol 2011; 12:86-9.
29. Moghimi-Dehkordi B, Vahedi M, Pourhoseingholi MA, Khoshkrood Mansoori B, Safaee A, Habibi M, et al. Economic burden attributable to functinal bowel disorders in Iran: A cross-sectional-based study. J Dig Dis 2011; 12:384-92.
30. Mohaghegh H, Soori H, Mnsoori B, Vahedi M, Moghimi-Dehkordi B, Pourhoseingholi MA, et al. Direct and Indirect medical costs of functional constipation: a population-based study. Int J Colorectal Dis 2011; 26:515-22.
31. Solomon M, Bonafede M, Pan K, Wilson K, Beam C, Chakravarti P, et al. Direct Medical Care Costs Among Pegylated Interferon Plus Ribavirin-Treated and Untreated Chronic Hepatitis C patients. Dig Dis Sci 2011; 56:3024-31.